OakChart

Neurogene Inc

NGNEHealthcare·Biotechnology·USA·Small·NASD·Nov 11 • 11:14 AM ET

25.70+0.42 (1.66%)
2026-11-11 17:15 CET
Market cap
505.89 USD m
Revenue, TTM
0.00 USD m
Net income, TTM
-119.18 USD m
Free cash flow, TTM
-95.93 USD m
EPS diluted, TTM
-5.56
P/E
-
Compare

Price

NGNE against its 20, 50 and 200-day averages
2050200beatmiss
20.0030.0040.00694K1.4MMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26NGNEclose 25.7020-day 25.8450-day 28.79200-day 28.1225.7052w high

41.1% under the 52-week high of 43.66 on 9 Jul 2026. 52-week low 15.93 on 5 Feb 2026. Last 15 sessions, 39.1% high to low

Profile

NGNE
52-week range, 35% of the way up
15.9343.66

Neurogene, Inc. is a clinical-stage biotechnology company, which engages in the development of product portfolio of genetic medicines for rare neurological diseases. The company was founded in May 2007 and is headquartered in New York, NY.

IndexRUT
Employees131
IPOMar 07, 2014
Beta1.73
ATR, 14d2.41
Rel volume0.28
Short float33.93%
Insider own16.27%
Inst own87.73%

Snapshot

6 groups

Valuation

IndexRUT
Market Cap532.01M
Enterprise Value179.84M
Income-119.18M
Sales0.00M
Book/sh17.15
Cash/sh17.38
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees131
IPOMar 07, 2014

Ratios

P/E-
Forward P/E-
PEG-
P/S-
P/B1.50
P/C1.48
P/FCF-
EV/EBITDA-
EV/Sales-
Quick Ratio19.96
Current Ratio19.96
Debt/Eq0.02
LT Debt/Eq0.01
Option/ShortYes / Yes

Earnings

EPS (ttm)-5.56
EPS next Y-5.60
EPS next Q-1.28
EPS this Y-25.14%
EPS next Y-5.61%
EPS next 5Y-5.37%
EPS past 3/5Y0.52% -45.84%
Sales past 3/5Y- -
EPS Y/Y TTM-25.59%
Sales Y/Y TTM-100.00%
EPS Q/Q-5.87%
Sales Q/Q-
EarningsNov 09 BMO
EPS/Sales Surpr.22.68% -

Ownership

Insider Own16.27%
Insider Trans-0.29%
Inst Own87.73%
Inst Trans12.10%
ROA-35.80%
ROE-38.42%
ROIC-33.17%
Gross Margin-
Oper. Margin-
Profit Margin-
SMA20-0.54%
SMA50-10.73%
SMA200-8.62%
Trades-

Technical

Shs Outstand20.69M
Shs Float16.76M
Short Float33.93%
Short Ratio18.52
Short Interest5.69M
52W High43.66 -41.14%
52W Low15.93 61.33%
Volatility9.51% 9.87%
ATR (14)2.41
RSI (14)46.52
Beta1.73
Rel Volume0.28
Avg Volume306.94K
Volume26,364

Performance

Perf Week-6.82%
Perf Month19.20%
Perf Quarter-27.87%
Perf Half Y-21.21%
Perf YTD24.76%
Perf Year-16.75%
Perf 3Y85.69%
Perf 5Y-79.89%
Perf 10Y-90.50%
Recom1.00
Target Price76.44
Prev Close25.28
Price25.70
Change %1.66%

Analyst ratings

latest 10 of 11
DateActionAnalystRating changeTargetImplied
Oct 08, 2026InitiatedJJP MorganOverweight$60+133.5%
Jun 03, 2026InitiatedRRodman & RenshawBuy$70+172.4%
Jun 17, 2025InitiatedCCraig HallumBuy$50+94.6%
May 16, 2025DowngradeRRobert W. BairdOutperform → Neutral$24-6.6%
Jun 27, 2024InitiatedBBMO Capital MarketsOutperform$65+152.9%
Jun 11, 2024InitiatedRRobert W. BairdOutperform$54+110.1%
Apr 29, 2024InitiatedLLeerink PartnersOutperform$46+79.0%
Mar 21, 2024InitiatedWWilliam BlairOutperform$61+137.4%
Jan 08, 2024InitiatedHH.C. WainwrightBuy$45+75.1%
Jan 05, 2024InitiatedSStifelBuy$31+20.6%

Peers

Mkt cap
TickerCompanyMkt cap
TSHATaysha Gene Therapies Inc1.39B
ACADAcadia Pharmaceuticals Inc3.15B
RGNXRegenxbio Inc553.77M
LXEOLexeo Therapeutics Inc257.35M
QUREuniQure NV1.62B
ABEOAbeona Therapeutics Inc133.16M
SLDBSolid Biosciences Inc872.24M
VYGRVoyager Therapeutics Inc110.46M
KRYSKrystal Biotech Inc9.10B
PASGPassage Bio Inc12.29M

Insider trading

latest 14 of 15
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
McMinn RachelChief Executive OfficerSep 22 '26Option Exercise25.3275619,1421,345,063Oct 02 02:49 PM
Cvijic Christine MikailPresident and CFOJul 07 '26Sale36.134,200151,76384,040Jul 07 09:08 PM
Cvijic Christine MikailPresident and CFOJul 06 '26Sale36.0260021,61388,240Jul 07 09:08 PM
Cvijic Christine MikailPresident and CFOJul 02 '26Sale34.824,061141,41788,840Jul 02 06:42 PM
Cvijic Christine MikailPresident and CFOJul 01 '26Sale34.0673925,17092,901Jul 02 06:42 PM
Cvijic Christine MikailPresident and CFOMay 06 '26Sale31.259,600300,04393,640May 08 11:51 AM
Christine CvijicOfficerMay 06 '26Proposed Sale28.9414,400416,736May 06 04:14 PM
Cvijic Christine MikailPresident and CFOMar 26 '26Sale21.622,55855,316103,240Mar 30 05:38 PM
McMinn RachelChief Executive OfficerMar 26 '26Sale22.073,35273,9951,344,307Mar 30 05:38 PM
Jordan JulieChief Medical OfficerMar 26 '26Sale21.8982818,12812,472Mar 30 05:38 PM
Cobb StuartChief Scientific OfficerMar 13 '26Sale20.816,797141,44630,497Mar 17 06:01 PM
Cvijic Christine MikailPresident and CFOMar 13 '26Sale20.814,04584,176105,798Mar 17 06:01 PM
STUART COBBOfficerMar 13 '26Proposed Sale22.306,797151,573Mar 13 04:20 PM
Cvijic Christine MikailPresident and CFOFeb 27 '26Sale25.114,800120,526109,843Mar 03 05:03 PM

Held by

AUM
TickerCompanyAUM
VTIVanguard Morningstar Total Stock Market ETFAUM: 687.42B
IWMiShares Russell 2000 Index FundAUM: 77.38B
XBIState Street SPDR S&P Biotech ETFAUM: 10.50B
VXFVanguard Extended Market Index ETFAUM: 30.47B
IWNiShares Russell 2000 Value ETFAUM: 14.10B
IBBiShares Biotechnology ETFAUM: 11.36B
FESMFidelity Enhanced Small Cap Core ETFAUM: 6.82B
VTWOVanguard Russell 2000 Index ETFAUM: 16.75B
IWCiShares Micro-Cap ETFAUM: 1.22B
VHTVanguard Health Care ETFAUM: 21.51B

News

latest 14 of 198
  • Neurogene: Q3 Earnings Snapshot (Associated Press)
  • Neurogene Reports Third Quarter 2026 Financial Results and Highlights Recent Updates (Business Wire)
  • Neurogene Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) -7.00%
  • Neurogene to Participate in Upcoming Investor Conferences (Business Wire)
  • Neurogene Presents New Data at ESGCT Congress that Reinforce Key Differentiators of NGN-401 Gene Therapy for Rett Syndrome (Business Wire) +14.66%
  • Loading…
  • Neurogene Announces Upcoming Presentations Highlighting Key Differentiators of NGN-401 for Rett Syndrome at the ESGCT 33rd Annual Congress (Business Wire) +5.09%
  • Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
  • Neurogene to Participate in H.C. Wainwright 28th Annual Global Investment Conference (Business Wire)
  • Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
  • Neurogene: Q2 Earnings Snapshot (Associated Press)
  • Neurogene Reports Second Quarter 2026 Financial Results and Highlights Recent Updates (Business Wire)
  • Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
  • Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) -7.87% +13.02%

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q32026-11-09-1.050-1.358-1.0500.000.0010
2026Q22026-08-11-1.530-1.423-1.5290.000.009
2026Q12026-05-12-1.390-1.296-1.3870.000.008
2025Q42026-03-24-1.120-1.239-1.5970.000.008
2025Q32025-11-13-0.990-1.249-0.9900.000.006
2025Q22025-08-11-1.050-1.160-1.0460.000.007
2025Q12025-05-09-1.080-1.050-1.0790.000.007
2024Q42025-03-24-1.000-1.129-1.3140.000.006
2024Q32024-11-18-1.190-1.222-1.1930.000.006
2024Q22024-08-09-1.090-1.050-1.0920.930.006
2024Q12024-05-10-1.000-1.034-1.0010.000.005
2023Q42024-03-182.930-1.173-1.2090.000.003
2023Q32023-11-14-1.933-0.600-0.4080.000.001
2022Q32022-11-14---0.237---
2022Q22022-08-09---0.284---
2022Q12022-05-09---0.278---

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2019FY-51.400-48.067-2.5690.000.00
2020FY-12.800-14.000-0.6420.000.00
2021FY-22.000-22.486-1.1030.000.00
2022FY-20.800-19.700-4.3040.000.00
2023FY2.930-5.577-2.8320.000.00
2024FY-4.280-4.259-4.2780.930.91
2025FY-4.240-4.320-4.2400.000.00
2026FY--5.306--0.00
2027FY--5.604--0.00
2028FY--4.960--65.08
2029FY--1.990--162.2
2030FY-4.280--400.33

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q4S2026-11-095000.000.000.00
2026Q4S2026-10-075000.000.000.00
2026Q4S2026-08-114000.000.000.00
2026Q4S2026-06-054000.000.000.00
2026Q4S2026-05-135000.000.000.00
2026Q4S2026-04-275000.000.000.00
2026Q4S2026-03-244000.000.000.00
2026Q4S2026-02-263000.000.000.00
2026Q4S2025-11-142000.000.000.00
2026Q4S2025-11-112000.000.000.00
2026Q4S2025-11-102000.000.000.00
2026Q4S2025-11-092000.000.000.00
2026Q4R2026-11-09521-1.43-1.64-1.25
2026Q4R2026-10-26500-1.46-1.64-1.20

Estimate history

EPS, annual-2.14-1.343-2.569-0.642-1.103-4.304-2.832-4.278-4.237-5.5609
Period201720182019202020212022202320242025TTM
EPS, quarterly-1.193-1.314-1.079-1.046-0.99-1.597-1.387-1.529-1.048
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Sales, annual025000000.92500
Period201720182019202020212022202320242025TTM
Sales, quarterly000000000
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Shares, annual23.47223.53737.99742.19642.45712.82412.82414.85515.4920.694
Period201720182019202020212022202320242025MRQ
Shares, quarterly13.01114.85514.9314.26914.77515.4915.61615.83120.694
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Total Revenue0.000.000.930.000.000.000.000.0025.00
Cost of Goods Sold Incl. D&A3.273.193.253.263.202.281.820.34-
Gross Profit-3.27-3.19-2.32-3.26-3.20-2.28-1.82-0.34-
Selling, General and Administrative Excl. Other126.65100.0280.2852.3253.3258.4239.7324.1048.52
Research and Development94.7874.8960.9244.3947.5139.1624.346.3232.79
Other Operating Expense0.000.000.000.000.000.000.000.000.00
Operating Income-129.92-103.21-82.61-55.58-56.52-60.70-41.55-24.44-23.52
Interest Expense-0.010.010.010.00--0.000.00
Unusual Expense0.000.120.000.000.000.000.0046.5210.40
Net Income Before Taxes-119.18-90.35-75.14-36.32-55.19-60.69-33.28-69.44-31.59
Income Taxes0.000.000.000.000.000.000.000.000.00
Consolidated Net Income-119.18-90.35-75.14-36.32-55.19-60.69-33.28-69.44-31.59
Net Income From Continuing Operations-119.18-90.35-75.14-36.32-55.19-60.69-33.28-69.44-31.59
Net Income-119.18-90.35-75.14-36.32-55.19-60.69-33.28-69.44-31.59
EPS (Recurring)-4.30-4.23-4.28-2.83-4.30-1.10-0.64-1.36-1.03
EPS (Basic, Before Extraordinaries)-5.56-4.24-4.28-2.83-4.30-1.10-0.64-2.57-1.34
EPS (Diluted)-5.56-4.24-4.28-2.83-4.30-1.10-0.64-2.57-1.34
EBITDA-126.65-100.02-79.36-52.32-53.32-58.42-39.73-24.10-
Non-Operating Income (Expense)10.7512.987.4719.281.330.018.281.522.34
Other After Tax Adjustments0.000.000.000.000.000.000.000.000.00
Stock Option Compensation Expense20.0014.188.321.421.2511.565.627.684.70
Price To Sales Ratio--434.14-----2.03
Gross Margin---251.03------
Operating Margin---8,930.27------94.10
Net Margin---8,123.68------126.34
Shares Outstanding20.6915.4914.8512.8212.8242.4642.2038.0023.54
Market Capitalization505.89505.89479.60248.52433.614,092.9011,899.369,362.421,016.81

Income statement, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q22025Q12024Q4
Total Revenue0.000.000.000.000.000.000.000.00
Cost of Goods Sold Incl. D&A0.820.810.850.790.810.810.760.80
Gross Profit-0.82-0.81-0.85-0.79-0.81-0.81-0.76-0.80
Selling, General and Administrative Excl. Other31.5535.8632.5026.7422.9925.2725.1620.71
Research and Development23.5225.4725.1520.6417.2419.3717.7615.35
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-32.38-36.67-33.35-27.53-23.80-26.08-25.92-21.51
Interest Expense---0.000.000.000.000.00
Unusual Expense0.000.000.000.000.000.000.000.00
Net Income Before Taxes-29.02-34.49-30.93-24.74-20.95-22.02-22.65-19.51
Income Taxes0.000.000.000.000.000.000.000.00
Consolidated Net Income-29.02-34.49-30.93-24.74-20.95-22.02-22.65-19.51
Net Income From Continuing Operations-29.02-34.49-30.93-24.74-20.95-22.02-22.65-19.51
Net Income-29.02-34.49-30.93-24.74-20.95-22.02-22.65-19.51
EPS (Recurring)-1.05-1.53-1.39-1.60-0.99-1.05-1.08-1.31
EPS (Basic, Before Extraordinaries)-1.05-1.53-1.39-1.60-0.99-1.05-1.08-1.31
EPS (Diluted)-1.05-1.53-1.39-1.60-0.99-1.05-1.08-1.31
EBITDA-31.55-35.86-32.49-26.74-22.99-25.27-25.16-20.71
Non-Operating Income (Expense)3.352.182.422.802.854.073.272.00
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense5.157.863.633.363.373.414.052.49
Price To Sales Ratio------265.80367.11
Shares Outstanding20.6915.8315.6215.4914.7814.2714.9314.85
Market Capitalization505.89496.97313.98319.09247.33213.22174.83479.60

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY
Cash & Short Term Investments269.01312.40197.1682.02142.47192.56143.0976.93108.08
Short Term Receivables0.460.650.600.990.000.000.000.000.00
Inventories0.000.000.000.000.000.000.000.000.00
Other Current Assets2.112.872.591.711.521.970.500.240.74
Total Current Assets271.58315.92200.3584.72143.99194.52143.6077.17108.83
Net Property, Plant & Equipment15.4618.4920.9524.5517.2213.722.830.400.91
Total Investments and Advances0.340.340.510.000.880.000.000.000.00
Intangible Assets---0.000.130.350.57-0.00
Deferred Tax Assets0.570.71-------
Other Assets1.220.970.760.001.051.930.030.050.60
Total Assets289.18336.44222.57109.27163.26210.52147.0277.62110.33
Short Term Debt Incl. Current Port. of LT Debt3.063.002.600.701.220.710.620.000.00
Accounts Payable1.951.342.600.620.531.321.600.700.00
Other Current Liabilities11.3910.8217.785.326.895.862.523.9210.96
Total Current Liabilities16.4115.1622.976.658.647.894.744.6310.96
Long Term Debt6.839.4312.37248.3511.7611.410.590.010.03
Provision for Risks Charges0.000.000.000.000.000.000.000.000.00
Deferred Tax Liabilities0.570.71-------
Other Liabilities0.480.771.210.000.000.000.000.310.45
Total Liabilities24.2926.0736.55255.0020.4019.305.344.9511.44
Non-Equity Reserves0.000.000.000.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.000.000.000.00
Common Equity264.89310.38186.02-145.74142.86191.22141.6972.6798.89
Total Shareholders Equity264.89310.38186.02-145.74142.86191.22141.6972.6798.89
Accumulated Minority Interest0.000.000.000.000.000.000.000.000.00
Total Equity264.89310.38186.02-145.74142.86191.22141.6972.6798.89
Total Liabilities & Stockholders Equity289.18336.44222.57109.27163.26210.52147.0277.62110.33
Book Value Per Share17.1020.8914.51-11.363.364.533.733.094.21
Tangible Book Value Per Share17.1020.8914.51-11.363.364.523.713.094.21
Full-Time Employees1311079156917036851
Price to Book Ratio1.472.162.274.1028.6562.2366.0813.9948.37
Return on Assets-28.88-26.88-21.46-40.50-32.47-18.61-61.82-33.61-37.92
Return on Equity-31.41-30.28-25.91-48.53-36.33-19.99-64.79-36.82-41.21
Return on Invested Capital-33.25-23.50-18.31-53.78-39.25-16.42-48.81-43.46-50.73
Quick Ratio16.5520.848.7212.7416.6724.6630.2816.689.93
Current Ratio16.5520.848.7212.7416.6724.6630.2816.689.93

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Net Income-117.38-90.35-75.14-36.32-55.19-60.69-33.28-69.44-31.59
Depreciation3.233.093.203.263.202.281.820.34-
Other Funds (Non Cash)16.609.827.31-14.341.8611.565.9255.665.44
Funds from Operations-97.55-77.44-64.64-47.40-50.13-46.86-25.54-13.44-26.15
Extraordinary Item0.000.000.000.000.000.000.000.000.00
Changes in Working Capital2.670.27-5.96-4.02-2.70-0.700.97-1.95-5.43
Cash from Operating Activities-94.88-77.17-70.60-51.42-52.82-47.56-24.58-15.39-31.58
Capital Expenditures-1.05-1.18-0.81-0.32-2.23-3.26-2.22-0.88-0.05
Net Assets From Acquisitions0.000.000.000.000.000.000.000.00-
Sale of Fixed Assets and Businesses0.000.000.000.000.000.000.000.19-
Purchase or Sale of Investments-81.5315.19-124.455.000.000.000.000.0056.00
Purchase of Investments-472.14-269.51-198.450.000.000.000.000.000.00
Sale Or Maturity of Investments390.61284.7074.005.000.000.000.000.0056.00
Other Uses0.000.000.00-1.290.000.000.000.000.00
Other Sources0.000.000.0022.240.000.000.000.000.00
Cash from Investing Activities-82.5914.00-125.2625.64-2.23-3.26-2.22-0.6955.95
Cash Dividends Paid0.000.000.000.000.000.000.000.000.00
Change in Capital Stock186.6330.49191.270.1766.530.7877.1882.250.60
Repurchase of Common Pref Stock0.000.000.000.000.000.000.000.000.00
Sale of Common Pref Stock186.6330.49191.270.1766.530.7877.1882.250.60
Proceedsfrom Stock Options185.4730.14189.590.0066.460.3771.5280.690.00
Issuance or Reduction of Debt, Net-0.03-0.06-0.05-0.03-0.00-0.05-0.05-0.01-0.03
Change in Long Term Debt-0.03-0.06-0.05-0.03-0.00-0.05-0.05-0.01-0.03
Issuance of Long Term Debt0.000.000.000.000.000.000.000.000.00
Reduction of Long Term Debt-0.03-0.06-0.05-0.03-0.00-0.05-0.05-0.01-0.03
Net Financing Active Other Cash Flow0.000.00-7.1492.340.000.000.000.000.00
Other Financing Activities Uses0.000.00-7.140.000.000.000.000.000.00
Cash from Financing Activities186.6030.43184.0792.4866.530.7377.1482.240.57
Exchange Rate Effect------0.000.01-0.05
Net Change in Cash9.13-32.74-11.7966.7011.48-50.0950.3466.1724.90
Free Cash Flow-95.93-78.36-71.41-51.74-55.05-50.82-26.79-16.27-31.63
Preferred Dividends (Cash Flow)-0.000.000.000.000.000.000.000.00
Deferred Taxes & Investment Tax Credit-0.000.000.000.000.000.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Cash & Short Term Investments359.72225.39243.18269.01265.41274.52
Short Term Receivables0.240.430.250.460.861.31
Inventories0.000.000.000.000.000.00
Other Current Assets2.642.693.122.114.023.16
Total Current Assets362.60228.52246.56271.58270.29278.99
Net Property, Plant & Equipment13.2514.0114.9815.4615.9116.89
Total Investments and Advances0.340.340.340.340.340.34
Deferred Tax Assets---0.57--
Other Assets1.711.501.271.221.291.10
Total Assets377.90244.36263.14289.18287.83297.32
Short Term Debt Incl. Current Port. of LT Debt3.013.033.053.063.103.13
Accounts Payable2.293.294.681.951.542.06
Other Current Liabilities12.8715.1911.1311.3910.0610.25
Total Current Liabilities18.1621.5018.8716.4114.7115.44
Long Term Debt4.545.326.086.837.107.83
Provision for Risks Charges0.000.000.000.000.000.00
Deferred Tax Liabilities---0.57--
Other Liabilities0.410.410.410.480.480.79
Total Liabilities23.1127.2325.3624.2922.2924.06
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity354.79217.13237.78264.89265.54273.25
Total Shareholders Equity354.79217.13237.78264.89265.54273.25
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity354.79217.13237.78264.89265.54273.25
Total Liabilities & Stockholders Equity377.90244.36263.14289.18287.83297.32
Book Value Per Share17.1513.7215.2317.1017.9719.15
Tangible Book Value Per Share17.1513.7215.2317.1017.9719.15
Full-Time Employees---131--
Price to Book Ratio1.472.071.181.150.910.76
Return on Assets-35.80-41.02-34.10-28.88-37.67-35.38
Return on Equity-38.42-45.32-37.25-31.41-42.25-39.41
Return on Invested Capital-8.08-15.50-12.68-9.10-7.69-7.83
Quick Ratio19.9610.6313.0716.5518.3718.07
Current Ratio19.9610.6313.0716.5518.3718.07

Cash flow, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Net Income-28.34-34.18-30.93-23.92-21.17-22.80
Depreciation0.800.810.850.760.780.79
Other Funds (Non Cash)3.067.662.793.091.952.27
Funds from Operations-24.48-25.71-27.29-20.07-18.44-19.74
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital-4.082.181.173.40-1.28-0.43
Cash from Operating Activities-28.55-23.53-26.12-16.67-19.72-20.17
Capital Expenditures-0.31-0.35-0.28-0.11-0.13-0.16
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.00
Purchase or Sale of Investments-164.266.2146.5229.9922.546.95
Purchase of Investments-237.04-111.77-83.48-39.85-78.23-63.04
Sale Or Maturity of Investments72.78117.98130.0069.84100.7769.99
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities-164.575.8646.2429.8822.416.79
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock159.885.960.2020.599.870.07
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock159.885.960.2020.599.870.07
Proceedsfrom Stock Options159.125.940.0020.429.780.00
Issuance or Reduction of Debt, Net-0.00-0.00-0.01-0.02-0.01-0.01
Change in Long Term Debt-0.00-0.00-0.01-0.02-0.01-0.01
Issuance of Long Term Debt0.000.000.000.000.000.00
Reduction of Long Term Debt-0.00-0.00-0.01-0.02-0.01-0.01
Net Financing Active Other Cash Flow0.000.000.000.000.000.00
Other Financing Activities Uses0.000.000.000.000.000.00
Cash from Financing Activities159.885.950.2020.579.860.06
Net Change in Cash-33.24-11.7220.3233.7812.56-13.33
Free Cash Flow-28.86-23.88-26.40-16.79-19.84-20.34

Revenue breakdown

Pharmaceutical Preparations2024: 925.00K
United States2024: 925.00K

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-3033.93%5.7M16.8M291.23K
2026-10-1530.39%5.1M16.8M265.65K
2026-09-3029.61%5.0M16.8M269.17K
2026-09-1519.52%3.3M16.8M238.65K
2026-08-3119.74%3.1M15.9M231.01K
2026-08-1419.15%3.0M15.9M213.98K
2026-07-3119.01%3.0M15.8M209.52K
2026-07-1518.52%2.9M15.8M210.44K
2026-06-3026.73%3.4M12.5M169.13K
2026-06-1528.32%3.5M12.5M156.15K
2026-05-2928.30%3.5M12.5M162.97K
2026-05-1528.76%3.6M12.5M180.35K
2026-04-3030.08%3.7M12.4M174.85K
2026-04-1528.53%4.0M14.1M161.94K
2026-03-3132.42%4.0M12.4M167.66K
2026-03-1331.44%3.9M12.4M172.99K
2026-02-2729.72%3.7M12.4M174.36K
2026-02-1329.17%3.6M12.4M170.55K
2026-01-3029.05%3.6M12.4M199.98K
2026-01-1528.61%3.5M12.4M217.17K

Option chain

expiry 2026-11-20
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
call15.008.0012.900.005.0210.000.000.851-0.3630.009
call17.505.5010.300.003.9360.000.000.810-0.3470.011
call20.003.107.900.003.2630.000.000.754-0.3160.013
call22.501.005.500.002.4420.000.000.699-0.2870.014
call25.000.004.902.402.8701160.000.612-0.2410.015
call30.000.054.900.053.9751.003.000.527-0.3550.016
call35.000.000.050.051.7791480.000.153-0.0920.009
call40.000.004.900.052.2972430.000.129-0.1040.008
call45.000.004.900.051.69914.000.000.022-0.0190.002
call50.000.004.900.001.9330.000.000.019-0.0200.002
put15.000.004.900.006.9700.000.00-0.149-0.3610.009
put17.500.004.901.075.7243.000.00-0.189-0.3460.011
put20.000.004.900.654.5696.000.00-0.244-0.3150.013
put22.500.004.901.713.6012.000.00-0.308-0.2790.014
put25.000.004.000.952.75781.000.00-0.388-0.2380.015
put30.003.007.000.002.6620.000.00-0.473-0.3500.016
put35.007.5012.000.003.3820.000.00-0.967-0.0130.003
put40.0012.5017.000.004.0050.000.00-0.974-0.0140.002
put45.0017.5022.000.004.4340.000.00-0.978-0.0140.002
put50.0022.5027.000.004.8330.000.00-0.981-0.0150.002

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-0910-QQuarterly report pursuant to Section 13 or 15(d)2026-09-30SEC
2026-11-098-KCurrent report2026-11-09SEC
2026-10-07SCHEDULE 13GSEC
2026-10-06SCHEDULE 13GSEC
2026-10-024Statement of changes in beneficial ownership of securities2026-09-22SEC
2026-08-14SCHEDULE 13G/ASEC
2026-08-14SCHEDULE 13GSEC
2026-08-14SCHEDULE 13G/ASEC
2026-08-1110-QQuarterly report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-08-118-KCurrent report2026-08-11SEC
2026-07-074Statement of changes in beneficial ownership of securities2026-07-06SEC
2026-07-02424B5SEC
2026-07-024Statement of changes in beneficial ownership of securities2026-07-01SEC
2026-07-028-KCurrent report2026-06-30SEC
2026-06-30424B5SEC
2026-06-298-KCurrent report2026-06-29SEC
2026-06-164/A2024-01-16SEC
2026-06-164/A2024-06-14SEC
2026-06-164/A2025-06-12SEC
2026-06-163/A2023-12-18SEC
2026-06-088-KCurrent report2026-06-08SEC
2026-06-048-KCurrent report2026-06-03SEC
2026-05-128-KCurrent report2026-05-12SEC
2026-05-1210-QQuarterly report pursuant to Section 13 or 15(d)2026-03-31SEC
2026-05-084Statement of changes in beneficial ownership of securities2026-05-06SEC
2026-05-074Statement of changes in beneficial ownership of securities2026-05-05SEC
2026-05-06144Filing for proposed sale of securities under Rule 144.SEC
2026-04-203Initial statement of beneficial ownership of securities2026-04-20SEC
2026-04-208-KCurrent report2026-04-20SEC
2026-04-16DEFA14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-090000
2026-080000
2026-0700339.96K4
2026-060000
2026-0500300.04K1
2026-040000
2026-0300373.06K5
2026-0200120.53K1
2026-010000
2025-120000
2025-110000

Institutional holders

Manager% owned
Samsara BioCapital, LLC10.87%
Casdin Capital, LLC9.78%
Redmile Group, LLC8.94%
RTW INVESTMENTS, LP8.62%
EcoR1 Capital, LLC8.05%
BlackRock, Inc.6.70%
BAKER BROS. ADVISORS LP6.28%
BALYASNY ASSET MANAGEMENT L.P.5.18%
Trails Edge Capital Partners, LP4.52%
TORONTO DOMINION BANK4.31%

Funds

Fund% owned
iShares Russell 2000 ETF1.88%
Franklin Biotechnology Discovery Fund1.10%
Fidelity Advisor Biotechnology Fund0.89%
VANGUARD EXTENDED MARKET INDEX FUND0.80%
iShares Russell 2000 Value ETF0.67%
PGIM Jennison Health Sciences Fund0.63%
VANGUARD TOTAL STOCK MARKET INDEX FUND0.62%
Fidelity Small Cap Index Fund0.62%
Fidelity Enhanced Small Cap Core ETF0.58%
iShares Biotechnology ETF0.56%

OakChart. NGNE. Cached 15 minutes.